공고 • Jun 30
Mingchen Health Co.,Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Mingchen Health Co.,Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 공고 • Jun 05
Mingchen Health Co.,Ltd. Announces Final Dividend for 2025, Payable on June 9, 2026 Mingchen Health Co.,Ltd. announced final profit distribution plan to be implemented (A shares) for 2025: CNY 0.50000000 for the year 2025. Record date:08 June 2026. Ex-date: 9 June 2026. Payment date: 9 June 2026. Declared Dividend • Jun 05
Dividend of CN¥0.05 announced Shareholders will receive a dividend of CN¥0.05. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (54% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 40% to shift the payout ratio to a potentially unsustainable range, which is more than the 31% EPS decline seen over the last 5 years. 공고 • Apr 28
Mingchen Health Co.,Ltd., Annual General Meeting, May 22, 2026 Mingchen Health Co.,Ltd., Annual General Meeting, May 22, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China 공고 • Mar 31
Mingchen Health Co.,Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Mingchen Health Co.,Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 공고 • Dec 31
Mingchen Health Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Mingchen Health Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 공고 • Sep 30
Mingchen Health Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Mingchen Health Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 공고 • Jul 02
Mingchen Health Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Mingchen Health Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 공고 • May 21
Mingchen Health Co.,Ltd. (SZSE:002919) announces an Equity Buyback for CNY 50 million worth of its shares. Mingchen Health Co.,Ltd. (SZSE:002919) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 50 million worth of its A shares. The shares will be repurchased at a price of not more than CNY 23 per share. The repurchased shares will be used for equity incentives or employee stock ownership plans. The shares will be repurchased out of own funds of the company. The plan will be valid for 12 months. 공고 • Apr 29
Mingchen Health Co.,Ltd., Annual General Meeting, May 20, 2025 Mingchen Health Co.,Ltd., Annual General Meeting, May 20, 2025, at 13:30 China Standard Time. 공고 • Mar 31
Mingchen Health Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Mingchen Health Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 공고 • Dec 31
Mingchen Health Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 Mingchen Health Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2023). Revenue: CN¥320.0m (down 30% from 3Q 2023). Net income: CN¥36.4m (down 45% from 3Q 2023). Profit margin: 11% (down from 14% in 3Q 2023). Buy Or Sell Opportunity • Sep 30
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to CN¥14.96. The fair value is estimated to be CN¥11.93, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has declined by 26%. 공고 • Sep 30
Mingchen Health Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Mingchen Health Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.25 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.061 (down from CN¥0.25 in 2Q 2023). Revenue: CN¥302.9m (down 31% from 2Q 2023). Net income: CN¥15.6m (down 76% from 2Q 2023). Profit margin: 5.1% (down from 15% in 2Q 2023). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥11.50, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 22x in the Personal Products industry in China. Total loss to shareholders of 61% over the past year. New Risk • Aug 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change). Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥13.43, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 24x in the Personal Products industry in China. Total loss to shareholders of 55% over the past year. 공고 • Jun 29
Mingchen Health Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Mingchen Health Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 공고 • May 30
Mingchen Health Co.,Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2024 Mingchen Health Co.,Ltd. implemented final cash dividend (tax included) of CNY 1.5 per 10 shares (A shares) for 2023, payable on 31 May 2024 with record date of 30 May 2024 and ex-date of 31 May 2024. 공고 • Apr 30
Mingchen Health Co.,Ltd., Annual General Meeting, May 20, 2024 Mingchen Health Co.,Ltd., Annual General Meeting, May 20, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China Reported Earnings • Apr 29
First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.15 in 1Q 2023). Revenue: CN¥361.8m (down 11% from 1Q 2023). Net income: CN¥44.8m (up 31% from 1Q 2023). Profit margin: 12% (up from 8.4% in 1Q 2023). 공고 • Mar 30
Mingchen Health Co.,Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Mingchen Health Co.,Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥25.54, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 27x in the Personal Products industry in China. Total returns to shareholders of 2.6% over the past year. New Risk • Feb 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). High level of non-cash earnings (30% accrual ratio). Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥21.47, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 23x in the Personal Products industry in China. 공고 • Dec 29
Mingchen Health Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024 Mingchen Health Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Dec 25
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥24.79, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 27x in the Personal Products industry in China. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥32.38, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 30x in the Personal Products industry in China. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.22 loss in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.22 loss in 3Q 2022). Revenue: CN¥458.7m (up 110% from 3Q 2022). Net income: CN¥66.2m (up CN¥111.8m from 3Q 2022). Profit margin: 14% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. 공고 • Sep 30
Mingchen Health Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023 Mingchen Health Co.,Ltd. announced that they will report Q3, 2023 results on Oct 30, 2023 Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.18 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.18 in 2Q 2022). Revenue: CN¥437.8m (up 124% from 2Q 2022). Net income: CN¥65.5m (up 157% from 2Q 2022). Profit margin: 15% (up from 13% in 2Q 2022). Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.007 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.007 in 1Q 2022). Revenue: CN¥406.8m (up 173% from 1Q 2022). Net income: CN¥34.1m (up CN¥32.5m from 1Q 2022). Profit margin: 8.4% (up from 1.1% in 1Q 2022). The increase in margin was driven by higher revenue. Board Change • Mar 14
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 4 experienced directors. No highly experienced directors. Employee Representative to the Supervisory Board Jianhui Yu is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.